Revenue distribution by sectors:

• Respiratory care: approx. 70%
• Acute care: approx. 20%
• Surgical products and others: approx. 10%

TOP 3 markets and their percentage shares:

• USA: approx. 45%
• Europe: approx. 25%
• Asia-Pacific: approx. 20%

Fisher & Paykel Healthcare Corporation Limited generates the majority of its revenue from respiratory care, driven by the increasing demand for respiratory protection devices and ventilation solutions. The U.S. market is the largest single market for the company, followed by Europe and the Asia-Pacific region. These markets benefit from an aging population and an increased need for medical devices.

Production Sites:

• New Zealand
• Mexico

Fisher & Paykel Healthcare Corporation Limited produces the majority of its products in New Zealand, where the company's headquarters are also located. In addition, the company operates a production facility in Mexico to more efficiently serve the demand in North and South America.

This strategic distribution of production sites enables the company to optimize production costs and shorten delivery times, contributing to an improved competitiveness in the global market.

Revenue Growth: Estimated 8-10% annually (2025) Focus on R&D Investments: 10% of revenue (2025)

Fisher & Paykel Healthcare Corporation Limited pursues a growth strategy that heavily relies on research and development (R&D). The company invests about 10% of its revenue in R&D to develop innovative products and strengthen its market position. These investments aim to develop new technologies in respiratory and acute care, as well as in sleep therapy.

Another focus of the growth strategy is geographical expansion. Fisher & Paykel Healthcare plans to increase its presence in emerging markets to benefit from the rising demand for medical devices in these regions.

Additionally, the company emphasizes strategic partnerships and acquisitions to expand its product portfolio and enter new markets. These measures are intended to support the estimated annual revenue growth of 8-10% and ensure long-term competitiveness.

Main raw materials: Plastic resins, silicones, aluminum

Countries of origin:

• Plastic resins: USA, China
• Silicones: Germany, Japan
• Aluminum: Australia, Canada

Fisher & Paykel Healthcare Corporation Limited imports a variety of raw materials needed for the production of their medical devices and products. Plastic resins and silicones are essential materials for the production of respiratory and ventilation devices. Aluminum is commonly used in the manufacturing of casings and other structural components.

The procurement of these materials is done from various countries to ensure quality and supply security. The USA and China are leading suppliers of plastic resins, while Germany and Japan are known for their high-quality silicones. Australia and Canada supply aluminum, valued for its lightness and strength.

Market share in ventilation therapy: 65% (2024)
Research & Development (R&D) expenses: 9% of revenue (2024)
Gross margin: 65% (2024)

Fisher & Paykel Healthcare Corporation Limited has a significant competitive advantage, especially in the field of ventilation therapy, where the company holds a market share of 65%. This demonstrates the strong market position and high acceptance of their products in the healthcare sector.

Another important aspect is the continuous investment in research and development, which accounts for approximately 9% of revenue. These investments enable the company to develop innovative products and differentiate itself from the competition.

The high gross margin of 65% underscores the efficiency and the company's ability to sell its products at a premium price, indicating a strong brand perception and customer loyalty. Together, these factors give Fisher & Paykel Healthcare a sustainable competitive advantage in the medical technology industry.

Institutional Investor Share: approximately 60% (2025, estimated) Insider Buys/Sells: No significant transactions in the last year (2025, estimated)

The institutional investor share in Fisher & Paykel Healthcare Corporation Limited is estimated to be around 60%. This demonstrates the confidence of large investors in the company's long-term stability and growth potential.

There have been no significant insider transactions in the past twelve months, indicating that the management and other insiders are satisfied with the current company strategy and see no need for major adjustments in their holdings.

Market share of Fisher & Paykel Healthcare: 22% (2025, estimated)

Top competitors and their market shares:

1. ResMed Inc.: 25%
2. Philips Healthcare: 20%
3. Medtronic: 15%
4. GE Healthcare: 10%
5. Smiths Medical: 8%

Moat of Fisher & Paykel Healthcare:

Fisher & Paykel Healthcare has a moderate moat, mainly characterized by its innovation capabilities and strong position in the respiratory care therapies sector. The company has built a reputation through continuous research and development, offering specialized products widely used in hospitals and home care settings.

In comparison to its competitors, ResMed has a stronger moat, particularly due to its leading position in sleep apnea therapies and a broad network of partnerships and distribution channels. Philips Healthcare and Medtronic benefit from their size and the diversification of their product portfolios, which also gives them a significant advantage.

Fisher & Paykel Healthcare needs to continue investing in research and development to maintain and potentially expand its technological edge. Competition in the medical technology industry is intense, and the ability to offer innovative and cost-effective solutions will be crucial for long-term success.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) Research & Development as a Percentage of Revenue: 9% (2024)

Fisher & Paykel Healthcare Corporation Limited recorded solid revenue growth of 8.5% in 2024, driven by strong demand for its medical products, especially in the respiratory care sector. The company also achieved a profit growth of 10.2%, indicating efficiency improvements and cost reduction measures.

Another positive aspect is the continuous investment in research and development, accounting for 9% of revenue. These investments are crucial for the company's future innovation capabilities and competitiveness.

Overall, Fisher & Paykel Healthcare demonstrates strong operational performance and a strategic focus on growth and innovation, making the stock a potentially good investment. However, investors should also consider macroeconomic factors and industry trends before making a final decision.

Dividend yield: 2.1% (2025, estimated)
Dividend history: Continuous payout over the last 5 years

Fisher & Paykel Healthcare Corporation Limited has regularly distributed dividends in recent years, indicating a reliable dividend policy. The dividend yield is estimated at 2.1% in 2025, which can be considered moderate compared to other companies in the industry.

The company has a solid financial foundation and demonstrates consistent profitability, supporting the reliability of dividend payments. The continuous payout over the last five years suggests that Fisher & Paykel Healthcare aims to provide shareholders with stable value.